Navigation Links
Nplate(TM) (Romiplostim) Receives Positive Opinion for Marketing Authorisation in the European Union
Date:11/21/2008

imbursement activities and outcomes and other such estimates and results. Forward-looking statements involve significant risks and uncertainties, including those discussed below and more fully described in the Securities and Exchange Commission (SEC) reports filed by Amgen, including Amgen's most recent annual report on Form 10-K and most recent periodic reports on Form 10-Q and Form 8-K. Please refer to Amgen's most recent Forms 10-K, 10-Q and 8-K for additional information on the uncertainties and risk factors related to our business. Unless otherwise noted, Amgen is providing this information as of June 15, 2008 and expressly disclaims any duty to update information contained in this news release.

No forward-looking statement can be guaranteed and actual results may differ materially from those we project. Discovery or identification of new product candidates or development of new indications for existing products cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate or development of a new indication for an existing product will be successful and become a commercial product. Further, preclinical results do not guarantee safe and effective performance of product candidates in humans. The complexity of the human body cannot be perfectly, or sometimes, even adequately modeled by computer or cell culture systems or animal models. The length of time that it takes for us to complete clinical trials and obtain regulatory approval for product marketing has in the past varied and we expect similar variability in the future. We develop product candidates internally and through licensing collaborations, partnerships and joint ventures. Product candidates that are derived from relationships may be subject to disputes between the parties or may prove to be not as effective or as safe as we may have believed at the time of entering into
'/>"/>

SOURCE Amgen
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. J. Craig Venter, Ph.D. Receives Double Helix Medal from Cold Spring Harbor Laboratory
2. Medarex Receives Milestone Payment for Investigational Antibody Targeting Integrin Receptors
3. Abbott Receives Complete Response Letter From FDA for Controlled-Release Hydrocodone With Acetaminophen
4. Life Recovery Systems Receives NIH Grant to Study Expanded Use of Its ThermoSuit System
5. Berlin Hearts EXCOR(R) Pediatric Receives Unconditional Investigational Device Exemption (IDE) Approval
6. Neuronascent, Inc. Receives Multiple Fundings for Its Neurogenesis Therapeutic Programs
7. TriReme Medical Inc. Receives CE Marking for Antares(TM) Coronary Stent System
8. Anthera Completes Special Protocol Assessment With FDA and Receives EMEA Scientific Advice on Development Path Toward Varespladib Approval
9. AstraZeneca Receives Six Months Pediatric Exclusivity for CASODEX(R) (bicalutamide) from the FDA
10. Helix Receives Approval to Open Sites in Germany for its Ongoing Clinical Trial With Topical Interferon Alpha-2b in Patients With Ano-Genital Warts
11. Enobia Pharma Receives FDA Orphan Drug Designation for Hypophosphatasia Product Candidate ENB-0040
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)...  Omeros Corporation (NASDAQ: OMER ) ... (IND) to evaluate OMS824 in Huntington,s disease has ... Administration (FDA). OMS824 selectively inhibits phosphodiesterase 10 (PDE10), ... linked to a wide range of diseases that ... has shown promising results in animal models directly ...
(Date:5/23/2013)... ATLANTA , May 23, 2013  Inhibikase ... treatments, announced today that it will present new ... at an industry conference sponsored by the PML ... Biogen Idec).  JC polyomavirus (JCV) is the causative ... host-directed tyrosine kinase inhibitor in an extended release ...
(Date:5/23/2013)... , May 23, 2013 ... MKT: NSPR), the leader in embolic protection stents, ... (MGuard for Acute ST Elevation Reperfusion) trial demonstrating ... bare metal and drug eluting stents in all-cause ... patients.  Results from the trial were presented at ...
Breaking Medicine Technology:Investigational New Drug Application Cleared by FDA for OMS824 in Huntington's Disease 2Investigational New Drug Application Cleared by FDA for OMS824 in Huntington's Disease 3Investigational New Drug Application Cleared by FDA for OMS824 in Huntington's Disease 4Inhibikase Therapeutics to present at Industry Conference on Drug-Induced Progressive Multifocal Leukoencephalopathy (PML) 2InspireMD's MGuard Embolic Protection Stent (EPS) Shows Lower Mortality Rate in STEMI Patients at Six Months Compared to Control Group 2InspireMD's MGuard Embolic Protection Stent (EPS) Shows Lower Mortality Rate in STEMI Patients at Six Months Compared to Control Group 3InspireMD's MGuard Embolic Protection Stent (EPS) Shows Lower Mortality Rate in STEMI Patients at Six Months Compared to Control Group 4InspireMD's MGuard Embolic Protection Stent (EPS) Shows Lower Mortality Rate in STEMI Patients at Six Months Compared to Control Group 5
(Date:5/23/2013)... (PRWEB) May 23, 2013 Teen birth rates ... according to new data released today by the ... the teen birth rate dropped at least 15% in 48 ... , There were also dramatic declines among all racial/ethnic groups ... ,     Birth rates declined 40% or more for Hispanic teens ...
(Date:5/23/2013)... May 23, 2013 To better ... DORMA company, is pleased to announce the release ... for its pacesetting space division products. Provided by ... wallcoverings, the new patterns and colors represent a ... Through meetings with a team of Koroseal experts, ...
(Date:5/23/2013)... can cause rapidly progressing, life threatening meningitis and meningococcal ... have not known how it attaches to the human ... attaches to the airway to colonise", People can be ... while some people progress to invasive disease. To ... how the bacterium colonises the airway. Now that the ...
(Date:5/23/2013)... According to a new market report ... Subscriber Data Management (SDM); Telecom Application Server; Service Creation ... – 2018)", published by MarketsandMarkets, the SDP Market is ... CAGR of 9.15% from 2013 to 2018. , Browse:, ... 84 Figures , 189 Pages ...
(Date:5/23/2013)... May 23, 2013 Verndale, an ... the launch of Current Digital, a business dedicated ... and digital marketing needs. Companies now view content ... business necessity. This can often leave agencies placed ... on preselected software platforms that they may not ...
Breaking Medicine News(10 mins):Health News:Modernfold Debuts New Colors and Patterns for Space Division Products 2Health News:New discovery in fight against deadly meningococcal disease 2Health News:Service Delivery Platform (SDP) Market Is Growing at a CAGR of 9.15% & to Reach $6.94 Billion by 2018 - New Report by MarketsandMarkets 2Health News:Service Delivery Platform (SDP) Market Is Growing at a CAGR of 9.15% & to Reach $6.94 Billion by 2018 - New Report by MarketsandMarkets 3Health News:Verndale Launches Current Digital, a Technology Partner for Ad and Creative Agencies 2Health News:Verndale Launches Current Digital, a Technology Partner for Ad and Creative Agencies 3
... being punched by electrical pulses could give better delivery ... treatments //including cancer therapy and gene therapy are limited ... cell membranes. Researchers in San Diego, California, have been ... which involves punching tiny holes into cell membranes using ...
... visions of adult stem cells as a less honestly questionable ... ability to sprout different cell types has spawned debate between ... who say it has life-saving potential. The new findings challenge ... directly produce cell types of other tissues and organs.// It ...
... Food and Drug Administration recommended that three popular allergy drugs ... FDA does not have to follow the advice of its ... for making a decision. // ,"Drugs are prescription ... good and harm. Claritin, Allegra and Zyrtec have almost no ...
... Tea derived from the plants Camellia sinensis contains polyphenols ... flavanols, which gives the tea its antioxidant properties. Polyphenols ... oxidative stress. , ... occur naturally in the body and an increased amount ...
... to a new study shows that women with ... 'good' cholesterol when they take oestrogen.// Previous research suggests ... heart disease. Now doctors at Forest University have discovered ... profile responds to HRT. ,An analysis of over ...
... in University of Texas, a novel blood test can detect ... to predict who might get Alzheimer's disease.Researchers at the School ... a similar blood test would work in people, but the ... ruins brain cells and is the cause of Alzheimer's. Some ...
Cached Medicine News:Health News:A question on study of Adult Stem Cell 2Health News:A question on study of Adult Stem Cell 3Health News:Blood test may aid foretell Alzheimer's 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: